RT期刊文章SR电子T1非痴呆老年人日间极度嗜睡预测β-amyloid积累增加:一项纵向PiB-PET神经学神经学研究(S14.004)摩根富林明乔FD Lippincott Williams &威尔金斯SP S14.004 VO 88是16补充A1迭戈卡瓦略A1 Erik圣路易斯A1 David Knopman A1布拉德利Boeve A1 V首页al劳A1玫瑰花蕾罗伯茨A1米歇尔Mielke A1斯科特Przybelski A1罗纳德·彼得森A1 Clifford杰克A1 Prashanthi Vemuri年2017 UL //www.ez-admanager.com/content/88/16_Supplement/S14.004.abstract AB目的:测试假设基线日间极度嗜睡(EDS)预测后续β-amyloid积累纵向模式的非痴呆老年人社区居住。背景:老化与增加白天嗜睡,已与老年人认知能力下降有关。然而,目前尚不清楚是否EDS与阿尔茨海默病(AD)病理,尤其是β-amyloid积累,鉴于睡眠似乎促进β-amyloid间隙。设计/方法:以人群为基础的梅奥诊所研究样本的老化,我们确定了283名年龄在70岁及以上的非痴呆的人至少有两个串行PiB-PET扫描和睡眠问卷调查完成。EDS被定义为埃普沃思嗜睡量表得分≥10。多元线性回归模型适合AD-related六个区域(前额,前额叶、前扣带回、cingulate-precuneus时间,和顶叶)探索是否EDS在基线预测变化的淀粉积累两个串行扫描,而控制基线年龄、性别、APOE4,教育、区域加以积极(SUVR≥1.4),体育活动,心血管并发症(肥胖、高血压、高脂血症、糖尿病),减少了睡眠时间,睡眠期间呼吸道症状(打鼾和/或目睹了呼吸暂停),抑郁和间隔扫描。结果:基线EDS显著增加β-amyloid积累在眼窝前额,前扣带和扣带/楔前叶区域模型包括所有科目。然而,联想的强度是强PiB-positive地区。EDS预测进一步增加β-amyloid积累前扣带(0.06,95%置信区间ci: 0.02 - -0.1, p = 0.007),扣带/楔前叶(0.076;95%置信区间:0.03—-0.12,p = 0.002),顶叶皮层(0.058,95%置信区间ci: 0.01 - -0.11, p = 0.03)的子集受试者淀粉样积极的在这些地区的基线。结论:EDS在非痴呆老年人增加率β-amyloid积累特别是与默认模式网络相关的区域(静)。静地区容易受到淀粉积累增加,表明治疗睡眠障碍的潜在EDS可能是通道途径对预防β-amyloid在这些领域积累。研究支持:NIHDisclosure:卡瓦略博士没有披露。 Dr. St. Louis has received personal compensation for activities with Axovant, Inc. and Inspire, Inc. Dr. Knopman has received personal compensation for activities with Lundbeck Pharmaceuticals.Dr. Knopman has received research support from Lilly Pharmaceuticals, Biogen and TauRX. Dr. Boeve has received research support from GE Healthcare, FORUM Pharmaceuticals, C2N Diagnostics and Axovant. Dr. Lowe received personal compensation for activities with Bayer Pharmaceuticals as a consultant. Dr. Roberts has nothing to disclose. Dr. Mielke has received personal compensation for activities with Lysosomal Therapeutics, Inc. as a consultant. Dr. Mielke has received research support from Biogen. Dr. Przybelski has nothing to disclose. Dr. Petersen received personal compensation for activities with Merck, Roche, Genentech, Biogen, and Eli Lilly and Co. Dr. Jack has received personal compensation for activities with Janssen Research & Development, LLC by providing consulting services. Dr. Jack has received research support from the National Institutes of Health (R01-AG011378, RO1-AG041851, RO1-AG037551. Dr. Vemuri has nothing to disclose.